Clinical Trial Detail

NCT ID NCT03637491
Title A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Pfizer
Indications

Advanced Solid Tumor

lung non-small cell carcinoma

pancreatic ductal adenocarcinoma

Therapies

Avelumab + Binimetinib + Talazoparib

Avelumab + Binimetinib

Age Groups: senior adult

Additional content available in CKB BOOST